Your shopping cart is currently empty

ADH-6, a tripyridylamide compound, impedes the self-assembly of the aggregation-nucleating subdomain of mutant p53 DNA-binding domain (DBD). By targeting and dissociating mutant p53 aggregates in human cancer cells, ADH-6 reinstates p53's transcriptional activity, culminating in cell cycle arrest and apoptosis, thereby holding potential for cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $2,570 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $3,380 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $4,600 | 10-14 weeks | 10-14 weeks |
| Description | ADH-6, a tripyridylamide compound, impedes the self-assembly of the aggregation-nucleating subdomain of mutant p53 DNA-binding domain (DBD). By targeting and dissociating mutant p53 aggregates in human cancer cells, ADH-6 reinstates p53's transcriptional activity, culminating in cell cycle arrest and apoptosis, thereby holding potential for cancer research. |
| Molecular Weight | 640.64 |
| Formula | C29H36N8O9 |
| Cas No. | 2227429-65-2 |
| Smiles | N(C(=O)C=1N=C(OCCCC)C(N(=O)=O)=CC1)C2=C(OCCCN)N=C(C(NC3=C(OCCCN)N=C(C(OC)=O)C=C3)=O)C=C2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.